eHealth Initiative

ehidc.org

eHealth Initiative and Foundation (eHI) is a Washington DC-based, independent, non-profit organization whose mission is to drive improvements in the quality, safety, and efficiency of healthcare through information technology. eHI is a multi-stakeholder collaborative, convening executives from every group in healthcare, to discuss, identify, and share best practices that transform the delivery of healthcare. Working with its membership, eHI advocates for the use of health IT that is practical, sustainable, and addresses stakeholder needs, particularly those of patients.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharmacy Market

M-PHARMA AND KYOWA KIRIN SIGN EXCLUSIVE LICENSE AGREEMENT FOR COMMERCIALIZATION OF ILOFOTASE ALFA IN JAPAN

AM-Pharma | September 08, 2021

news image

AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, and Kyowa Kirin Co., Ltd, a global specialty pharmaceutical company that strives to create new value through the pursuit of advances in life sciences and technologies, today announced that they have entered into an exclusive license agreement under which Kyowa Kirin gains the rights to develop and commercialize ilofotase alfa, AM-Pharma’s proprietary recombinant human alkaline phosphatase. ...

Read More

Pharmacy Market

CASI PHARMACEUTICALS ANNOUNCES EXIT OF JUVENTAS INVESTMENT TO STRENGTHEN BALANCE SHEET

CASI Pharmaceuticals, Inc. | September 26, 2022

news image

CASI Pharmaceuticals, Inc. a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products announced that CASI Biopharmaceuticals Co., Ltd, a subsidiary of CASI Pharmaceuticals, Inc. entered into an Equity Transfer Agreement with Shenzhen Jiadao Gongcheng Equity Investment Fund, LLP pursuant to which CASI Wuxi agreed to transfer its equity interest in Juventas Biotechnology Co., Ltd. amounting to 12.0098% total Juventas equity ...

Read More

AMAZON INTENSIFIES PUSH INTO AUSTRALIAN PHARMACY WITH TRADEMARK APPLICATION

Smh | June 01, 2020

news image

Retail giant Amazon has intensified its push into Australia's highly competitive pharmaceuticals sector, brushing off industry opposition with a fresh trademark application for a range of private-label over-the-counter medications. Amazon filed the application for the 'BasicCare' trademark on Friday and refers to Amazon-branded medication which shoppers can buy directly from the e-commerce giant. The move comes as Amazon faces a fight with the Pharmacy Guild of Australia over a previ...

Read More

Business Insights, PHARMA TECH

MTTI RECEIVES CHINESE PATENT FOR EVATHERA TECHNOLOGY

Molecular Targeting Technologies, Inc. | December 07, 2022

news image

Molecular Targeting Technologies, Inc. announces the issuance of Chinese Patent CN109153641B covering MTTI’s lead radiotherapeutic product, EBTATE™ and others in its EvaThera™ platform. Approval of “Chemical conjugates of Evans blue derivatives and their use as radiotherapeutic and imaging agents” follows issued patents in the US, Europe, Singapore, and Japan this past year. EBTATE is a new generation of peptide receptor radiotherapeutic drug that has...

Read More
news image

Pharmacy Market

M-PHARMA AND KYOWA KIRIN SIGN EXCLUSIVE LICENSE AGREEMENT FOR COMMERCIALIZATION OF ILOFOTASE ALFA IN JAPAN

AM-Pharma | September 08, 2021

AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, and Kyowa Kirin Co., Ltd, a global specialty pharmaceutical company that strives to create new value through the pursuit of advances in life sciences and technologies, today announced that they have entered into an exclusive license agreement under which Kyowa Kirin gains the rights to develop and commercialize ilofotase alfa, AM-Pharma’s proprietary recombinant human alkaline phosphatase. ...

Read More
news image

Pharmacy Market

CASI PHARMACEUTICALS ANNOUNCES EXIT OF JUVENTAS INVESTMENT TO STRENGTHEN BALANCE SHEET

CASI Pharmaceuticals, Inc. | September 26, 2022

CASI Pharmaceuticals, Inc. a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products announced that CASI Biopharmaceuticals Co., Ltd, a subsidiary of CASI Pharmaceuticals, Inc. entered into an Equity Transfer Agreement with Shenzhen Jiadao Gongcheng Equity Investment Fund, LLP pursuant to which CASI Wuxi agreed to transfer its equity interest in Juventas Biotechnology Co., Ltd. amounting to 12.0098% total Juventas equity ...

Read More
news image

AMAZON INTENSIFIES PUSH INTO AUSTRALIAN PHARMACY WITH TRADEMARK APPLICATION

Smh | June 01, 2020

Retail giant Amazon has intensified its push into Australia's highly competitive pharmaceuticals sector, brushing off industry opposition with a fresh trademark application for a range of private-label over-the-counter medications. Amazon filed the application for the 'BasicCare' trademark on Friday and refers to Amazon-branded medication which shoppers can buy directly from the e-commerce giant. The move comes as Amazon faces a fight with the Pharmacy Guild of Australia over a previ...

Read More
news image

Business Insights, PHARMA TECH

MTTI RECEIVES CHINESE PATENT FOR EVATHERA TECHNOLOGY

Molecular Targeting Technologies, Inc. | December 07, 2022

Molecular Targeting Technologies, Inc. announces the issuance of Chinese Patent CN109153641B covering MTTI’s lead radiotherapeutic product, EBTATE™ and others in its EvaThera™ platform. Approval of “Chemical conjugates of Evans blue derivatives and their use as radiotherapeutic and imaging agents” follows issued patents in the US, Europe, Singapore, and Japan this past year. EBTATE is a new generation of peptide receptor radiotherapeutic drug that has...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us